Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - August 2010


Expertise in Neuropharmacology





Latest News

Adrian Newman-Tancredi Ph.D. will be presenting at the 23rd meeting of the ECNP (European College of Neuropsychopharmacology
on Sunday 29 August 2010
in Amsterdam, Netherlands.

Presentation title: "Searching for an optimised pharmacological cocktail: focus on antipsychotics with combined dopamine D2 and serotonin 5-HT1A receptor activity".

If you are attending this meeting, don't hesitate to meet Adrian and learn about his work on antipsychotics.  
                                                Read more




NeuroAct Communication advises lifescience companies and funding agencies on drug discovery programmes in neuropharmacology.

  • Take a fresh look at neuroscience research programs from an expert pharmacology perspective.

  • Provide an independent evaluation of target selection and validation criteria.

  • Examine product differentiation and target profiles.

  • Give a detailed assessment of development candidates prior to go/no-go decision making.

If you need assistance in these areas get in touch.




NeuroAct Communication is an independent consulting service founded by Adrian Newman-Tancredi Ph.D.,
a pharmaceutical industry professional with 17 years' experience in neuropharmacology and drug discovery.
ind out more about Adrian in his Executive Profile.



New Publications

Adrian Newman-Tancredi has recently authored several publications on antipsychotics and serotonin receptor pharmacology. For information about Adrian's expertise in this area, Read more.
"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives."
Newman-Tancredi A (2010)
Curr Opin Invest Drugs 11(7):802-12
Read abstract
"The central serotonin2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity."
Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, Spampinato U. (2010)
J Neurochem. 2010 Jun 7. [Epub]
Read abstract
"Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors."
Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P. (2010)
Br J Pharmacol. 160(8):1929-40.
Read abstract